Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Neovascular membrane and pregnancy. Treatment with bevacizumab
Journal Information
Vol. 87. Issue 9.
Pages 297-300 (September 2012)
Share
Share
Download PDF
More article options
Visits
2807
Vol. 87. Issue 9.
Pages 297-300 (September 2012)
Short communication
Neovascular membrane and pregnancy. Treatment with bevacizumab
Membrana neovascular y embarazo. Tratamiento con bevacizumab
Visits
2807
I. Gómez Ledesma
Corresponding author
igomezledesma@yahoo.com

Corresponding author.
, M.Á. de Santiago Rodriguez, I. Follana Neira, F. León Garrigosa
Servicio de Oftalmología, Hospital Universitario Virgen de la Vega, Salamanca, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (6)
Show moreShow less
Abstract
Clinical case

A female in her sixth month of pregnancy, with a history of refractive surgery, consulted due to a metamorphopsia and decrease in visual acuity in the right eye. A presumed ocular histoplasmosis syndrome (POHS) and a subfoveal choroidal neovascular membrane were observed in the fundoscopy. Two monthly doses of intravitreal bevacizumab were given after the labor, but the third dose was never infected as the patient became pregnant again. She subsequently had a spontaneous miscarriage.

Discussion

During pregnancy treatment with intravitreal bevacizumab during pregnancy is controversial as it may increase the risk of miscarriage during the first trimester.

Keywords:
Bevacizumab
Intravitreal injections
Choroidal neovascularization
Miscarriage
Pregnancy
Resumen
Caso clínico

Mujer en el sexto mes de gestación, con antecedentes de cirugía refractiva, que consulta por metamorfopsias y disminución de la agudeza visual en el ojo derecho. En la exploración se observa una membrana neovascular coroidea subfoveal asociada al síndrome de presunta histoplasmosis ocular (SPHO). Tras el parto se realiza tratamiento con dos dosis mensuales de bevacizumab intravítreo. La tercera dosis no se realiza por nuevo embarazo, observándose posteriormente aborto espontáneo sin causa conocida.

Discusión

El tratamiento con bevacizumab intravítreo durante el embarazo es controvertido, ya que es posible que aumente el riesgo del aborto espontáneo durante el primer trimestre.

Palabras clave:
Bevacizumab
Inyecciones intravítreas
Neovascularización coroidea
Aborto espontáneo
Embarazo

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos